help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deftos, MD, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deftos, MD, L. J.
Endocrinology Vol. 138, No. 2 519-520
Copyright © 1997 by The Endocrine Society

ARTICLES

Editorial: There’s Something Fishy and Perhaps Even Fowl about the Mammalian Calcitonin Receptor and Its Ligand1

Leonard J. Deftos, MD

The Department of Medicine University of California, San Diego, San Diego, California 92161 and The San Diego Veterans Affairs Medical Center La Jolla, California 92161

Address all correspondence and requests for reprints to: Leonard J. Deftos, M.D., San Diego Veterans Affairs Medical Center, University of California-San Diego, 3350 La Jolla Village Drive, Room 3172, Mail Code 111C, San Diego, California 92161. E-mail: ljdeftos{at}ucsd.edu


   Introduction
Top
 Introduction
References
 
Two papers in this issue of Endocrinology sustain the trajectory of the research on the mammalian calcitonin (CT) receptors that was launched by their cloning (1). Both studies have important basic and clinical implications. Wada et al. (2) examined the molecular and cellular mechanisms of the regulation of the mouse CT receptor (CTR) in osteoclasts by CT, itself, and by glucocorticoids. They showed that glucocorticoids enhanced CTR gene expression predominantly through increased gene transcription and that CTs induced posttranscriptional destabilization of the receptor messenger RNA (mRNA). Neither agent changed the affinity of CT’s binding to its receptor. Guiza et al. (3) investigated the molecular mass and degree of N-linked glycosylation of six cloned CTRs from different species. They provided direct evidence for the glycoprotein nature of the CTR and demonstrated that the extent and pattern of glycosylation are dependent upon the host cell. Although glycosylation can be important in ligand binding in some receptors (1, 3), these studies using glycosylated and partially deglycosylated CTR preparations demonstrated no significant differences among them in binding affinity or specificity for CT. These molecular mechanisms may help to explain two aspects of the use of CT as a drug: its decline in effectiveness upon continual administration and its enhanced effectiveness by glucocorticoids (1, 4, 5).

While these two studies continue to unravel the molecular twine of ligand-receptor interaction, neither implicated any changes in affinity nor specificity of ligand binding as molecular mechanisms. This lack of change in receptor affinity reveals something fishy about the mammalian CTR: the fact that salmon CT (SCT) and other nonmammalian CTs have a higher affinity and potency for all mammalian CT receptors, including human, than any of the native CTs that have been identified, whether homologous or heterologous to the receptor under study (1, 5, 6). This enhanced potency of SCT and the nonmammalian CTs in mammals has been repeatedly demonstrated in many clinical and biological studies, and it is the basis for the more popular use of SCT in treating humans than human CT (HCT) (4, 5, 6). In addition to the two studies in this issue of Endocrinology, many elegant studies of the CTs and the CTRs have provided important structure-function insights into the molecular enigma of SCT’s high affinity for the mammalian CTR. A brief review of the comparative studies of the CTs and CTRs and the molecular insights they provide can serve as a starting point for an inquiry into the evolutionary riddle of the high affinity of SCT for essentially all mammalian CTRs.

Over a dozen species of the CTs have been cloned and/or sequenced (5). These 32 amino acid peptides can be separated into three classes based on structural and biological similarities: teleost/avian, artiodactyl, and rat/human; the first are nonmammalian CTs of ultimobranchial (UB) gland origin, the second and third, thyroid gland CTs. All share many common features, including a 1–7 amino-terminal disulfide bridge, a conserved 4–7 sequence, a glycine at residue 28, and a carboxy-terminal proline amide residue. However, substantial divergence resides in the interior of the molecule between residues 8–27, and SCT and HCT share only 50% of their amino acids. Complex functional studies (1, 5) reveal a simple canon: basic amino acid substitutions in the interior of the CT molecule enhance potency, perhaps by conferring a helical structure to this region. Because SCT and the nonmammalian CTs are more basic and thus helical than the mammalian CTs, they consequently have the most potency, even in mammalian systems.

Comparative studies of the CTRs also provide some insights into the enhanced potency of nonmammalian CTs for mammalian CTRs (1). The CTRs are members of a subfamily of seven-transmembrane domain, G protein-coupled receptors that includes receptors for several other peptide hormones. CTRs have been cloned from the porcine, human, rat, mouse, and rabbit, but a nonmammalian CTR has yet to be cloned. CTRs are most robustly expressed in osteoclasts but are also expressed in many other sites, including the central nervous system. The mammalian CTRs share common structural and functional motifs, signal through several pathways, and can exist in several isoforms with insert sequences and/or deletions in their intracellular and extracellular domains (1, 7, 8, 9). The similar architecture of the CTR with the PTH receptor subfamily member allows reciprocal signaling of chimeras and a common pattern of ligand interaction (10). Because CTRs are monogenic, these isoforms are likely to arise from alternative splicing of receptor mRNA. Some of the isoforms of the CTR seem to have differential ligand specificity (5, 8, 9). Studies with mutations and chimeras (1, 10, 11) have suggested the following model for CT-CTR interaction: the ligand is sandwiched between the receptor’s amino-terminus and transmembrane loops, with high affinity being conferred by the helicity of the internal, nonconserved basic sequences of the CT. Signal transduction through several pathways results from the interaction of the amino-terminus of CT with the transmembrane domain of the receptor. Thus, the ligand specificity of the CTR is determined by the membrane-embedded portion of the receptors, whereas the amino-terminal, extracellular domain of the receptors affects binding affinity for the respective agonist. SCT apparently conforms best to these structural requirements for binding and signaling of mammalian CTRs, perhaps also explaining in part its sustained receptor binding and activation of cAMP (7, 8, 9). While these tentative models of the CTRs and the CTs may help to explain the molecular basis of optimal ligand-receptor interactions, they do not directly address the evolutionary enigma: why are fish CTs orders of magnitude more potent in mammals than mammalian CTs?

The recently cloned receptor for CT-gene-related-peptide (CGRP) may provide some insights about regulation of the ligand specificity of the CTR (12, 13). Luebke et al. (12) cloned a 146-amino acid protein that binds with high affinity to CGRP, the alternate mRNA splice product of the CT gene. This newly identified protein has no homology to any known receptor. It seems rather to be a CGRP binding protein that confers specificity to the recently cloned CGRP receptor (13), the newest member of the G protein-coupled receptor family. A nonreceptor ligand binding mechanism similar to CGRP’s might exist that confers receptor specificity for the CTs, which are CGRPs’ splicing siblings (12, 13).

The isoforms of the CTR may also provide some clues about its evolutionary molecular biology. An isoform that is expressed in rat brain seems to preferentially recognize SCT, and binding sites for SCT are present at several sites in the CNS (9, 10, 14). Could it be that SCT or an SCT-like ligand is produced by mammals? There is some evidence for this in both man and murine. The presence and secretion of SCT-like immunoreactive material have been described in the CNS of several mammalian species, including humans (15, 16, 17). This location is consistent with a role of a SCT-like peptide acting as a neurotransmitter, perhaps through an SCT-specific isoform of the CTR (8, 9, 18). Another fishy link between human and murine mineral metabolism may be provided by stanniocalcin; this antihypercalcemic hormone originally identified in fish has been recently identified in humans (19). Finally it is also notable that another nonmammalian CT, chicken CT, also seems more potent in humans than human CT and may be expressed in humans (1, 5, 20). Cloning of the salmon CTR as well as the chicken CTR should provide insight into molecular interactions among CTs and their receptors and may provide the answer to another Darwinian riddle: which came first for human mineral metabolism, the chicken or the roe?


   Footnotes
 
1 This work was supported by the NIH, the National Cancer Institute, and the Department of Veterans Affairs. Back

Received November 19, 1996.


   References
Top
 Introduction
 References
 

  1. Goldring SR 1996 The structure and molecular biology of the calcitonin receptor. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of Bone Biology. Academic Press, New York, Chapter 33, pp 461–470
  2. Wada S, Udagawa N, Akatsu T, Nagata N, Martin TJ, Findlay DM 1996 Regulation by calcitonin and glucocorticoids of calcitonin receptor gene expression in mouse osteoclasts. Endocrinology 138:000–000
  3. Guiza M, Dowton M, Perry KJ, Sexton PM 1996 Electrophoretic mobility and glycosylation characteristics of heterogeneously expressed calcitonin receptors. Endocrinology 138:000–000
  4. Deftos LJ, First BP 1981 Calcitonin as a drug. Ann Int Med 96:192–197
  5. Deftos LJ 1996 Calcitonin. In: Favus MJ (ed) Primer on the Metabolism Bone Diseases and Disorders of Mineral Metabolism, ed. 3. Lippincott-Raven Press, New York, Chapter 14, pp 82–91
  6. Houssami S, Findlay DM, Brady CL, Martin TJ, Epand RM, Moore EE, Murayama E, Tamura T, Orlowski RC, Sexton PM 1995 Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation. Mol Pharmacol 47:798–809[Abstract]
  7. Suzuki H, Nakamura I, Takahashi N 1996 Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. Endocrinology 137:4685–4690[Abstract]
  8. Findlay DM, Houssami S, Christopoulos G, Sexton PM 1996 Homologous regulation of the rat C1a calcitonin receptor (CTR) in nonosteoclastic cells is independent of CTR messenger ribonucleic acid changes and cyclic adenosine 3', 5'-monophosphate-dependent protein kinase activation. Endocrinology 137:4576–4585[Abstract]
  9. Albrandt K, Mull E, Brady EMG, Herich J, Moore CX, Beaumont K 1993 Molecular cloning of two receptors from rat brain with high affinity for salmon calcitonin. FEBS Lett 325:225–232[CrossRef][Medline]
  10. Bergwitz C, Gardella TJ, Flannery MR, Potts Jr JT, Kronenberg HM, Goldring SR, Jüeppner H 1996 Full activation of chimeric receptors by hybrids between parathyroid hormone and calcitonin. J Biol Chem 271:26469–26472[Abstract/Free Full Text]
  11. Stroop SD, Nakamuta H, Kuestner RE, Moore EE, Epand RM 1996 Determinants for calcitonin analog interaction with the calcitonin receptor N-terminus and transmembrane-loop regions. Endocrinology 137:4752–4756[Abstract]
  12. Luebke AE, Dahl GP, Roos BA, Dickerson IM 1996 Identification of a protein that confers calcitonin gene-related peptide responsiveness to oocytes by using a cystic fibrosis transmbrane conductance regulator assay. Proc Natl Acad Sci USA 93:3455–3460[Abstract/Free Full Text]
  13. Aiyar N, Rand K, Elshourbagy NA, Zeng Z, Adamou JE, Bergman DJ, Li Y 1996 A cDNA encoding the calcitonin gene-related peptide type I receptor. J Biol Chem 271:11325–11329[Abstract/Free Full Text]
  14. Henke H, Tobler PA, Fischer JA 1983 Localization of salmon calcitonin binding sites in rat brain by autoradiography. Brain Rese 272:373–377[CrossRef][Medline]
  15. Deftos LJ 1987 Pituitary cells secrete calcitonin in the reverse hemolytic plaque assay. Biochem Biophys Res Commun 146:1350–1356[CrossRef][Medline]
  16. Shah GV, Deftos LJ, Crowley WR 1993 Synthesis and release of calcitonin-like immunoreactivity by anterior pituitary cells. Endocrinology 132:1367–1372[Abstract]
  17. Sexton PM, Hilton JM 1992 Biologically active salmon calcitonin-like peptide is present in rat brain. Brain Res 596:279–284[CrossRef][Medline]
  18. Hanna FWF, Smith DM, Johnston CF, Akinsanya KO, Jackson ML. Morgan DGA, Bhogal R, Buchannan KD, Bloom SR 1995 Expression of a novel receptor for the calcitonin peptide family and a salmon calcitonin-like peptide in the {alpha}-thyrotropin thyrotroph cell line. Endocrinology 136:2377–2395[Abstract]
  19. Olsen HS, Cepeda MA, Zhang Q-Q, Rosen CA, Vozzolo BL, Wagner GF 1996 Human stanniocalcin: a possible hormonal regulator of mineral metabolism. Proc Natl Acad Sci USA 93:1792–1796[Abstract/Free Full Text]
  20. Lasmoles F, Jullienne A, Day F, Minvielle S, Milhaud G, Moukhtar MS 1985 Elucidation of the nucleotide sequence of chicken calcitonin mRNA: direct evidence for the expression of a lower vertebrate calcitonin-like gene in man and rat. EMBO J 4:2603–2607[Medline]




This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deftos, MD, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deftos, MD, L. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals